Clinical research organization is expanding its operations in Asia through a partnership with a Taiwan-based firm.
PRA, which provides a variety of services to life science and medical firms, will work through its Taiwan subsidiary with LSK Global Pharma Services and Mediscience Planning.
Financial terms were not disclosed.
The deal gives PRA access to markets in Japan and South Korea.
"Through this collaboration, we are strongly positioned to meet the growing demand for pan-Asian clinical trials,” said PRA Executive Vice President Susan Stansfield.
PRA maintains 32 offices around the world and focuses on oncology, central nervous system, respiratory/allergy, cardiovascular and infectious diseases.
